Presence of EGFR mutation in pathologically non-malignant specimens from computed tomography-guided lung needle biopsies

Ueno,Tsuyoshi; Soh,Junichi; Hiraki,Takao; Asano,Hiroaki; Ichimura,Koichi; Shibamoto,Kentaro; Gobara,Hideo; Kanazawa,Susumu; Toyooka,Shinichi; Miyoshi,Shinichiro

doi:10.3892/ol.2011.471

Presence of EGFR mutation in pathologically non-malignant specimens from computed tomography-guided lung needle biopsies

Authors:
- Tsuyoshi Ueno
- Junichi Soh
- Takao Hiraki
- Hiroaki Asano
- Koichi Ichimura
- Kentaro Shibamoto
- Hideo Gobara
- Susumu Kanazawa
- Shinichi Toyooka
- Shinichiro Miyoshi
View Affiliations

Affiliations: Department of General Thoracic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan, Department of Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan, Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan
Published online on: November 3, 2011 https://doi.org/10.3892/ol.2011.471
Pages: 401-404

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Activating mutations of the epidermal growth factor receptor (EGFR) gene are characteristic of non-small cell lung cancer (NSCLC). EGFR mutations were previously detected in histologically normal lung tissue around NSCLC tumors. Computed tomography-guided lung needle biopsy (CTNB) is an accurate and useful technique for the diagnosis of lung tumors. However, pathologically non-malignant cases occasionally become apparent following lung tumor resection. In this study, we determined the EGFR mutational status of lung tumors diagnosed as non-malignant in CTNB specimens, but diagnosed as NSCLC following surgical resection. Between 2000 and 2008, 1,109 CTNBs were performed at Okayama University Hospital. Among them, 15 cases were initially diagnosed as non-malignant by CTNB, but diagnosed as NSCLC following surgical resection as a result of a high likelihood of malignancy by clinical findings. Twelve paired DNAs of CTNB and corresponding resected specimens were available to examine the EGFR mutational status using a mutant-enriched PCR assay. EGFR mutations were detected in one out of 12 CTNB specimens and three of the corresponding resected tumors. This case harbored the same EGFR mutation in the CTNB specimen and resected tumor, but not in the distant corresponding non-malignant lung tissue. Our results indicated that the detection of EGFR mutations may therefore aid the diagnosis of NSCLC in pathologically non-malignant CTNB specimens.

View Figures

View References

1	Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar
2	Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
3	Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, et al: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
4	Asano H, Toyooka S, Tokumo M, Ichimura K, Aoe K, Ito S, Tsukuda K, Ouchida M, Aoe M, Katayama H, et al: Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res. 12:43–48. 2006. View Article : Google Scholar : PubMed/NCBI
5	Shih JY, Gow CH, Yu CJ, Yang CH, Chang YL, Tsai MF, Hsu YC, Chen KY, Su WP and Yang PC: Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer. 118:963–969. 2006. View Article : Google Scholar
6	Soh J, Toyooka S, Aoe K, Asano H, Ichihara S, Katayama H, Hiraki A, Kiura K, Aoe M, Sano Y, et al: Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer. 119:2353–2358. 2006. View Article : Google Scholar : PubMed/NCBI
7	Otani H, Toyooka S, Soh J, Yamamoto H, Suehisa H, Kobayashi N, Gobara H, Mimura H, Kiura K, Sano Y, et al: Detection of EGFR gene mutations using the wash fluid of CT-guided biopsy needle in NSCLC patients. J Thorac Oncol. 3:472–476. 2008. View Article : Google Scholar : PubMed/NCBI
8	Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, Gazdar AF and Wistuba II: EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 65:7568–7572. 2005.PubMed/NCBI
9	Edey AJ and Hansell DM: Incidentally detected small pulmonary nodules on CT. Clin Radiol. 64:872–884. 2009. View Article : Google Scholar : PubMed/NCBI
10	Uskul BT, Turker H, Gokce M, Kant A, Arslan S and Turan FE: CT-guided transthoracic fine needle aspiration of pulmonary lesions: accuracy and complications in 134 cases. Tuberk Toraks. 57:177–185. 2009.PubMed/NCBI
11	Hiraki T, Mimura H, Gobara H, Iguchi T, Fujiwara H, Sakurai J, Matsui Y, Inoue D, Toyooka S, Sano Y, et al: CT fluoroscopy-guided biopsy of 1,000 pulmonary lesions performed with 20-gauge coaxial cutting needles: diagnostic yield and risk factors for diagnostic failure. Chest. 136:1612–1617. 2009. View Article : Google Scholar
12	Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
13	Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
14	He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N and Xu J: Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer. 125:2393–2399. 2009. View Article : Google Scholar : PubMed/NCBI
15	Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Lee JY, Yoo NJ and Lee SH: Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. Int J Cancer. 113:510–511. 2005. View Article : Google Scholar : PubMed/NCBI